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Abstract 
Pharmacogenetics (PGt), the study of a gene's influence on 
patient response to a drug, shows strong potential for 
explaining issues with efficacy related to antidepressant 
medications. Each year, antidepressants are one of the most 
commonly prescribed medications due to the millions of 
Americans affected by depression. Importantly, it is recog-
nized that there is wide interpatient variability in drug re-
sponse to antidepressants caused by genetic mutations, 
which can alter the pharmacodynamic (PD) and pharmacoki-
netic (PK) properties of various drugs used to treat depres-
sion. Proteins that are mainly involved in how patients 
respond to medications include receptors, drug-targeted pro-
teins, drug transport proteins and drug-metabolizing en-
zymes. Specifically in depression, variations in the serotonin 
reuptake transporter (SERT-1or5-HTT), N-acetyltransferase 
(NAT2), cytochrome P450 (CYP) 2C19, 2D6, and 1A2 can 
affect the outcomes of patients receiving certain antidepres-
sant medications. Utilizing PGt can help prevent the trial and 
error in prescribing antidepressants and lead to better pa-
tient outcomes in the treatment of depression. Pharmacists 
can utilize genetic information to help primary care physi-
cians choose drug regimens that are more likely to benefit 
their patients. Although advances are being made in this sub-
ject matter, some major efforts of future research will evalu-
ate the efficacy of drug regimens and the dosing of drugs 
based on patient genetics. 
Glossary:t 
Allele-Alternate sequences or versions of the same gene 
inherited from each parent. 
Extensive Metabolizers/Normal Metabolizer (EM/NM)-
An individual with two "normal-function" alleles relative to a 
drug-metabolizing enzyme. 
Genotype-The specific set of alleles inherited at a locus on 
a given gene. 
Haplotype-A series of polymorphisms that are inherited 
together. 
Indel-Insertion or deletion of deoxyribonucleic acid (DNA) 
either as single nucleotides or spanning regions of DNA in-
volving many nucleotides. 
Intermediate Metabolizers (IM)-In general, an individual 
with one "loss-of-function" allele and one "normal-
functional" allele relative to a drug-metabolizing enzyme. 
Personalized medicine-The use of patient-specific infor-
mation and biomarkers to make more informed choices re-
garding the optimal therapeutic treatment regimen for a 
given patient. 
Pharmacodynamics (PD)-The relationship between drug 
exposure and pharmacologic response. 
Pharmacogenetics (PGt)-The study of a gene involved in 
response to a drug. 
Pharmacogenomics (PGx)-Studying and understanding 
the genes, in some cases the entire genome, involved in re-
sponse to a drug. 
Pharmacokinetics (PK)-The relationship of time and drug 
absorption, distribution, metabolism and excretion. 
Phenotype- An individual's expression of a physical trait or 
physiologic function due to genetic makeup and environ-
mental and other factors. 
Polymorphisms-A mutation in DNA in a given population 
that may be observed at greater than 1 percent frequency. 
Poor Metabolizer (PM)-In general, an individual with two 
"reduced-function" or "loss of function" alleles relative to a 
drug-metabolizing enzyme. 
Reference Sequence Number (rs)-A unique and consis-
tent identifier of a given single nucleotide polymorphism 
(SNP). 
Single Nucleotide Polymorphism (SNP)-A variant DNA 
sequence in which a single nucleotide has been replaced by 
another base. 
Ultra Metabolizers (UM)-An individual with a "gain-of-
function" allele (e.g., overexpression ofa metabolic enzyme). 
Wild-Type Gene-The typical or normally occurring geno-
type of an organism. 
Introduction/Background 
According to statistics, one of every 10 adults in America 
have reported symptoms of depression, and specifically, ma-
jor depressive disorder (MDD) is one of the most commonly 
diagnosed disorders in the United States,2.3 These current 
numbers aside, it is also estimated that at least 10 percent of 
Americans will experience MDD at some point in their lives.4 
This trend in disorders is reflected in drug use as well. 
According to the U.S. Centers for Disease Control and Preven-
tion, in 2010, prescribers wrote nearly 122 million prescrip-
tions for antidepressant drugs-the third highest of any 
other type of medication prescribed out of the total 3.2 bil-
lion prescriptions written in both hospitals and doctors' of-
fices.s Altogether, the number of depressed patients plus the 
antidepressant medications they are prescribed each year 
makes it obvious that this type of mental disorder utilizes a 
significant portion of our health care system resources. 
In terms of current treatment guidelines for depression, 
health care professionals are first advised to manage patients 
with sleep hygiene and low-intensity psychosocial interven-
tions such as cognitive behavioral therapy.6After employing 
this nonpharmacologic therapy, the first-line drugs of choice 
for depression are antidepressants, specifically selective se-
rotonin reuptake inhibitors (SSRis).6,7 Depression is a disor-
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der of the brain involving neurotransmitters. The SSR!s, and 
other antidepressants, successfully target specific neuro-
transmitters, including serotonin, norepinephrine and some-
times dopamine.a 
As mentioned previously, SSR!s are the first-line pharma-
cologic choice for treatment of depression. In comparison to 
other antidepressant drugs, in general SSRls are safer and 
have fewer intolerable side effects.9 Some of the most com-
monly prescribed SSRls are fluoxetine (Prozac®), sertraline 
(Zoloft®), escitalopram (Lexapro®), Paroxetine (Paxil®), 
and citalopram (Celexa®).B Another factor to consider re-
garding the popularity of antidepressant drug use is the high 
frequency of a comorbid anxiety disorder. Almost 50 percent 
of patients diagnosed with depression are diagnosed with an 
anxiety disorder as we11.10 Some of the most common types 
of mental disorders diagnosable by Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM-V) criteria are 
depressive disorders, anxiety disorders, trauma- or stressor-
related disorders, and obsessive-compulsive and related dis-
orders.11 More specific examples include generalized anxiety 
disorder (GAD), panic disorder (PD), post-traumatic stress 
disorder (PTSD), seasonal affective disorder (SAD) and 
obsessive compulsive disorder (OCD), all of which have a 
first-line treatment that includes SSR!s per the American 
Psychological Association guidelines for treatment.12-14 
Overall, considering the popularity in use of antidepressant 
drugs, based on the number of prescriptions written per 
year, it would seem that antidepressants must be a success-
ful treatment strategy regarding depression and anxiety 
disorders. However, there is a downside to this type of treat-
ment that cannot be ignored. Despite the medication success-
fully treating patients for their mental disorders, the actual 
response to these drugs is very slow and delayed. It can take 
four to six weeks before patients will see the full effect of 
antidepressants.a According to current treatment guidelines 
it is recommended that individuals undergo an initial thera-
peutic trial of four to eight weeks to determine their 
response to the medication.7 Not only does it require this 
period of waiting to see the full therapeutic effects of the 
drug, but this also includes a delay in time before patients 
may exhibit adverse side effects from drug use as their body 
adjusts to the medicationJ,9 
The requirement of patience when using antidepressants can 
be a difficult feat to achieve when treating individuals with 
mental disorders. These patients are already experiencing 
symptoms that are negatively impacting their lives and are 
requiring treatment. Adding on the stress of "waiting" to see 
if the drug will work can prove to be a definite challenge for 
many individuals who seek an immediate "fix." Also, unfortu-
nately, there is the chance that the drug will not even reach 
therapeutic effects in the patient regardless of how long he 
or she waits (i.e., treatment-resistant depression). Another 
problem is that physicians use trial and error prescribing as 
the primary method of prescribing antidepressants. Trial and 
error prescribing is a method by which the physician 
"blindly" chooses a medication that tends to work, in hope 
that a response will be seen. This is very inefficient because it 
can take months before discovering an efficacious therapeu-
tic regimen for patients. The National Institute of Mental 
Health has published research that shows that patients who 
do not find success from their first medication usually find 
resolution with their second treatment on a different type of 
medication.a However, this fact can make it even more diffi-
cult for patients to accept when asked to "wait" for their ther-
apy to reach full effect. "It has been estimated that about 20 
to 30 percent of patients with major depression fail to re-
spond to treatment with a single antidepressant drug given 
in adequate dosage for an appropriate period."15 This is a 
problem to be addressed, and the answer may be a conse-
quence ofpharmacogenetics (PGt) . 
Like all other drugs, antidepressants possess pharmacody-
namic (PD) and pharmacokinetic (PK) properties. The PD 
characteristics relate to the therapeutic effects antidepres-
sants have on neurotransmitters in the brain, while the PK 
properties can result in increased drug exposure leading to 
adverse effects, or decrease exposure leading to treatment 
failure. Pharmacogenomics (PGx), looking across a larger 
number of genes relative to drug response, takes both PD 
and PK into account. Therefore, it can be assumed that PGx 
could be used to "screen and predict whether patients will 
respond to antidepressants and be able to tolerate the medi-
cations."7 
Depression and antidepressants actually serve as a perfect 
platform for PGx research since genetics play a large role in 
both the disease and drug therapy. First, most antidepressant 
drugs are metabolized via CYP450 enzymes, and it has al-
ready been proven through many studies that the CYP450 
enzymes have numerous variations and mutations based on 
different genes and alleles that exist within the human popu-
lation.1.15 Therefore, if professionals can identify specific 
polymorphisms in patients they can predict their inherent 
metabolic capacity to metabolize antidepressant drugs be-
fore ever beginning treatment. Second, depression itself has 
shown to be 40 to 50 percent due to "heritability." This 
means that nearly 50 percent of all cases of depression are 
actually related to genetics.4 That being said, if a family mem-
ber has previously responded well to a certain antidepres-
sant, this could be a positive indication that the same drug 
will also work for a relative with a similar genetic profile. 
Ultimately, health care professionals can use genetics first to 
designate a patient's predisposition for depression, and then 
add the use of PGx to determine their metabolic capacity to 
process antidepressant drugs. As a result, health care provid-
ers can have some expectation of treatment effects before 
beginning therapy and, thus, they can better predict drug 
responses to antidepressant medications and minimize the 
burdensome requirement to "wait."7 
In an attempt to transform subjective data into objective 
data, four distinct phenotypic categories have been created 
for placement of individuals based on their CYP450 genotype 
"star nomenclature." These include: poor metabolizer (PM), 
intermediate metabolizer (IM), extensive (normal) metabo-
lizer (EM;NM), and ultrarapid metabolizer (UM).1 For exam-
ple, PMs cannot metabolize the drug as efficiently as needed 
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which may result in increased side effects or even toxicity as 
the drug accumulates. If the medication is a prodrug, metabo-
lism by a CYP enzyme is required for activation, and in this 
case would be compromised leading to decreased efficacy. 
Conversely, a UM would metabolize an active drug very effi-
ciently, resulting in a decrease in efficacy and a greater dose 
would be required to achieve therapeutic levels. 
Due to the variance in patient outcomes and the need to 
know a patient's genetic composition for predicting the effec-
tiveness of an antidepressant, genetic testing of the genes 
that code for enzymes that metabolize antidepressant medi-
cations would help optimize therapy. Various companies ex-
ist that can perform this type of genetic testing for patients. 
One such company is Genelex Corporation. This company 
provides a software product called YouScript® which is a 
tool that can help pharmacists and other health care provid-
ers in the interpretation of genetic information. YouScript® 
includes a three-step process for patients interested in hav-
ing individual SNPs identified that are relevant to their dis-
ease state. First, the patient would need to talk with his or 
her physician to have a prescription form completed for the 
testing. Depending on what genes are being tested and a pa-
tient's insurance, the testing may be covered. Next, the pre-
scriber would follow the kit instructions and send in a cheek 
swab sample from the patient. After about five to seven days, 
the results of the genetic testing would be returned, which 
could be used by a physician to assess the likelihood of how 
effective a medication would be. Although there is some lag 
time to get the results of a genetic test, this is still less than 
the typical time to analyze the efficacy of an antidepressant 
through standard practice as described earlier. For a patient 
starting a new antidepressant therapy, he or she will not 
need their entire genome sequenced. Genetic variance needs 
to be identified for genes that are relevant to the antidepres-
sant medications a patient will be taking. As it relates to anti-
depressants, the genetic information for the genes that code 
for the enzymes NAT2, CYP2D6, CYP2C19, and CYP1A2, and 
the reuptake transporter 5-HTT may be needed depending 
on the medications being prescribed.16 Although these four 
enzymes and transporter are involved, the majority of anti-
depressants are metabolized in the liver by either CYP2D6 
and/or CYP2C19.17 By knowing and understanding a pa-
tient's genetic profile, physicians and pharmacists will be 
better able to serve a patient and individualize his or her 
therapeutic regime. 
Table 1. Polymorphisms for CYP2D6 16 
CYP2D6 Polymorphisms 
Active *1, *2, *35 
Cytochrome P450 2D6 (CYP2D6) 
Cytochrome P450 2D6 (CYP2D6) is an enzyme coded by 
CYP2D6 gene which is found on chromosome 22 and is ex-
pressed in many tissues, particularly the liver.17 This enzyme 
(CYP2D6) biotransforms approximately 25 percent of known 
drugs that are metabolized by the CYP family and is one of 
the most important enzymes for metabolism of antidepres-
sants.17 The CYP2D6 gene has more than 100 different varia-
tions, some of which are shown in Table 1.16,18,19 Depending 
on the SNPs, the enzyme could have active, inactive or par-
tially active function. Additionally, CYP2D6 is not considered 
an inducible enzyme (via drug interactions) and varied re-
sponses of the action of this enzyme among patients is due to 
their inherited genetics.20 Because there are so many differ-
ent alleles of CYP2D6, it can be a challenging gene in terms of 
determining if a medication will likely be effective.20 For anti-
depressants, CYP2D6 is important for the metabolism of 
SSRls and tricyclic antidepressants (TCA).16 Tricyclic antide-
pressants are hydroxylated by CYP2D6 to less active forms. 
The polymorphisms that a patient has will influence his or 
her likelihood to experience a therapeutic response or ad-
verse events. For example, a patient that is a poor metabo-
lizer because of inactive or partially active forms of the 
enzyme is at increased risk of experiencing adverse events 
because of elevated TCA plasma levels. In these individuals, 
alternative medications may be needed.lB In addition, medi-
cations can be metabolized by other enzymes, which may 
also be controlled by genes with many variants. 
Cytochrome P450 2C19 (CYP2C19) 
In addition to the CYP2D6 enzyme, cytochrome P450 2C19 
(CYP2C19) is also an important enzyme for the metabolism 
and activation of antidepressants. CYP2C19 is the gene cod-
ing for this enzyme which is found on chromosome 10 and 
also has a wide range of variation with as many as 34 poly-
morphisms identified.19,21 Some antidepressant medications 
such as amitriptyline, clomipramine, doxepin, imipramine 
and trimipramine are in a less active form and have to be 
demethylated to active metabolites by CYP2C19 in order to 
induce their therapeutic effect.18 In a patient that has a geno-
type for partially active or inactive CYP2C19 enzyme 
(Table 2), this individual may not achieve the desired re-
sponse because not enough of the compound is in the active 
form. By knowing the PGt of an individual prior to antide-
pressant medication prescribing, a health care professional 
could recognize that the patient would likely not respond to 
Inactive *3,*4,*5,*6,*7,*8,*11,*12,*14,*15,*19,*20 
Partially Active *9,*10,*17,*29,*41 
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Table 2. Polymorphisms for CYP2C19 16 
CYP2C19 Polymorphism 
Active *1 
Inactive/ 
*2,*3,*4,*5,*6,*7,*8,*12 Loss-of-Function 
Partially Active *9,*10 
Gain-of-function *17 
amitriptyline if he or she has a certain polymorphism of the 
CYP2C19 enzyme. This would help eliminate the guessing 
game of prescribing antidepressant medications. The varia-
tions of the enzymes that are genetically determined yet 
again demonstrate the need for genetic testing for people 
being prescribed a new antidepressant therapy. 
Cytochrome P450 1A2 (CYP1A2) 
Cytochrome P450 1A2 (CYP1A2) is another important cyto-
chrome P450 metabolic enzyme (comprising of 13 percent of 
all CYP proteins) that is coded by the CYP1A2 gene located at 
chromosome 15 with other CYPl genes (CYPlAl and 
CYPlBl).22,23 Over 100 substrates for CYP1A2 have been re-
ported including drugs such as caffeine (major substrate), 
procarcinogens and endogenous substrates. 22 Some impor-
tant inducers of CYP1A2 include cigarette smoking, proton 
pump inhibitors (esomeprazole and omeprazole), crucifer-
ous vegetables (cauliflower, cabbage, broccoli and similar 
green leafy vegetables), whereas some important inhibitors 
include ciprofloxacin (Cipro®) and other fluoroquinolones, 
fluvoxamine (Luvox®) (SSRI), oral contraceptives, verapamil 
(Calan®) and grapefruit juice; a more complete list can be 
found at http:/ /youscript.com/uploads/P450chart.pdf.16 
Also, similar to other main drug-metabolizing CYPs, a num-
ber of allelic variants have been identified that clearly ex-
plain the phenotypic variability in CYP1A2 gene expression 
or inducibility. 24 
Over 40 haplotype variants have been discovered in CYP1A2 
and only 12 of these variants have been clearly associated 
with one of four phenotypes including normal enzymatic 
activity, inducer of enzymatic activity, decreased or abol-
ished expressivity, or decreased enzymatic activity 
(inhibitor) with most being classified as inhibitors.19,zs The 
allele accounting for normal enzymatic activity is 
CYP1A2*1A. One important allelic variation in CYP1A2 is a 
SNP at nucleotide position 163 where adenosine (A) replaces 
cytosine (C) which is designated by 163C>A. This SNP has 
been reported to result in increased (induced) enzymatic 
activity and is noted by the reference sequence number (rs #, 
refSNP, rs) rs762551.2s.26 Three other allelic variations that 
decrease or abolish expression of CYP1A2 include *3, *4, and 
*6. The remaining seven allelic variations are clearly associ-
ated with phenotypes linked to decreased enzymatic func-
tion include *1C, *1K. *7, *8, *11, *15, *16.19,2s Relatively little 
is known about other CYP1A2 polymorphisms (SNPs) in 
terms of their functional consequences possibly due to lack 
of research because CYP1A2 is not as prevalent as other CYP 
enzymes and is not a major metabolizing enzyme of most 
drugs.26 
Within the classes of antidepressant drugs, fluvoxamine 
(Luvox®) is the only SSRI in which CYP1A2 plays a minimal 
role (5-10%) in metabolism.22 The metabolic pathway for 
fluvoxamine through CYP1A2 is methyl-ether demethylation, 
which is when a methyl ether is replaced with a hydroxyl 
group that causes the drug to be inactivated.22 Since CYP1A2 
plays a very minimal role in fluvoxamine metabolism, it is 
highly unlikely that the dosage will need to be adjusted in 
these patients. Coincidentally, a study done by Christensen 
et al. found that fluvoxamine is a strong inhibitor of CYP1A2 
and CYP2C19 due to results showing significant (40-50%) 
inhibitory effect on both enzymes even at low doses.27 Pa-
tients taking fluvoxamine need their medication profiles re-
viewed to identify medications that utilize CYP1A2 or 
CYP2C19 as a major metabolic pathway, due to the inhibitory 
effect of fluvoxamine. Primary care physicians will need to 
make dose adjustments for some medications or switch pa-
tients to a different drug regimen to avoid drug toxicity from 
occurring. Furthermore, patients may need therapy adjust-
ments if they choose certain diets or lifestyles (e.g., smoking) 
that induce or inhibit enzymatic activity of CYP1A2. There 
are a few other antidepressants that are major substrates for 
CYP1A2 including amitryptyline (Elavil®), chlorpromazine 
(Thorazine®), duloxetine (Cymbalta®), 1m1pramine 
(Tofranil®), olanzapine (Zyprexa®); a more complete list 
including antidepressants that are metabolized by CYP1A2 
and additionally CYP2D6, CYP2C19, and other enzymes can 
be found at http://www.plasmaspiegel.at/TDM_consensus_ 
document_2011.pdf.2B Undoubtedly, there is still an unmet 
need for research in determining variant allele associations 
with phenotype groups for CYP1A2. The hope is that future 
studies will be able to adequately guide recommendations 
for treatment adjustments for patient phenotypes that either 
affect metabolic efficiency or expressivity of CYP1A2.25 
Table 3. Polymorphisms for CYP1A2 19,zs 
Phenotype CYP1A2 Allele 
Wild-Type *1A 
Abolished/ 
*3,*4,*6 Decreased Expression 
Enzyme Inducer *1F 
Decrease Enzyme 
*1C,*1K,*7,*8,*11,*15,*16 Activity (Inhibitor) 
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Not all factors of drug response rely on hepatic metabolism. 
In the case of antidepressants, as well as many anticancer 
agents and other drugs, drug response is also determined by 
mutations in the expression of transporters and other cell 
proteins.16 In other words, a patient's CYP genotype is not 
the sole factor in determining their response to antidepres-
sant therapy. Currently, the U.S. Food and Drug Administra-
tion (FDA) recognizes 155 clinically significant biomarkers 
directly affecting patients' response and tolerance to medica-
tions.29 In a study by Lee and associates, a mutation in the 
gene coding for an intracellular signaling protein was associ-
ated with a significantly better response to SSRI therapy.30 
Dysfunctions in a protein controlling the activation of brain-
derived neurotrophic factor (8DNF) as well as the enzyme 
catechol 0-methyltransferase (COMT) gene have also been 
established in predicting antidepressant response out-
comes.31,32 These newly identified biomarkers affecting drug 
metabolism and response serve as future drug targets for 
better patient-specific therapy. 
N-acetyltransferase 2 (NAT2) 
N-acetyltransferase 2 (NAT2) is an enzyme coded by the 
gene NAT2 which is found at chromosome 8 (specific loca-
tion: p21.3-p23.1). This enzyme is responsible for acetylation 
of the nitrogen atom in many drugs, including antidepres-
sants.33 N-acetyltransferase 2 acts on 1 percent of drugs in 
current clinical use and is thought to contribute to the break-
down of different classes of drugs including antidepressants. 
The proportion of slow, intermediate, and rapid metabolizers 
(acetylators) is known to differ between different ethnic 
populations.16 The only specific inhibitor for NAT2 is aceta-
minophen which weakly inhibited the enzyme by 30.9 per-
cent in rapid acetylators and 19.3 percent in slow acetylators 
(no data for intermediate acetylators given).34 There are cur-
rently over 87 variants that have been identified in NAT2 
with the wild-type identified as NAT2*4.25 Allelic variations 
are associated to low enzymatic activity (*5, *6, *7, *14, *17, 
*22), rapid (normal) enzymatic activity (*11, *12, *13, *18, 
*20, *21, *23, *24, *25, *27), and no enzymatic activity (*15, 
*19A, *198).25 Three phenotypes are identified between 
varying alleles in these categories that can be classified as 
rapid (normal) acetylators (two rapid activity alleles), inter-
mediate acetylators (one low activity one rapid activity 
allele), or slow acetylators (two low activity alleles).35 As-
signing acetylator phenotype according to alleles is very 
challenging due to the fact that six different SNPs influence 
the phenotype presentation in which patients can have any 
Table 4. Polymorphisms for NAT2 25,35 
Phenotype NAT2 Allele 
Wild-Type (Rapid Enzymatic Activity) *4 
different number of them. In order to determine if patients 
are rapid, slow, or intermediate acetylators, a free online 
program called the NAT2 website predictor (NAT2PRED), 
http://nat2pred.rit.albany.edu, implements a pattern recog-
nition according to the combination of SNPs found in NAT2 
at positions 282, 341, 481, 590, 803 and 857.35 Patient SNPs 
in NAT2 can be identified by genetic testing, and the website 
allows selection between the different SNPs the patient may 
contain. Once submitted, the predictor assigns one of the 
three NAT2 phenotypes based on the combination of SNPs 
inputted whereby health care providers can make adjust-
ments to dosing of medications. 35 Clinicians should also be 
aware that NAT2 activity is also dependent upon hepatic and 
renal function status and age.16 Some dosing recommenda-
tions (for drugs impacted by NAT2) provided by 
youscript.com include starting at the lowest dose possible of 
a drug in which efficacy can be seen and employing thera-
peutic drug monitoring in intermediate acetylators and slow 
acetylators.16 Further studies are required to determine 
whether genotyping of NAT2 is clinically useful for determin-
ing a patient's dosage for efficacy of treatment and to avoid 
drug toxicity, especially in antidepressants.2s 
Serotonin Reuptake Transporter (SERT-1or5-HTT) 
The serotonin reuptake transporter 1 (SERT-1 or 5-HTT) is 
coded by the gene, SLC6A4, and is a protein mainly found on 
serotonergic presynaptic neurons in the brain, playing a 
primary role in the termination of the synaptic effects of se-
rotonin (5-hydroxytryptamine or 5-HT) following its pre-
synaptic release.37-39 The role of the transporter is to carry 
extracellular 5-HT across the cell membrane into the neuron, 
via a conformational change, which allows the cell to either 
recycle intracellular 5-HT into storage vesicles or metabolize 
unpackaged intracellular 5-HT with enzymes.37·39 The pro-
moter activity of SLC6A4 is located at chromosome 17 
(specific location: q11.1-q12) and may contain an indel 
(insertion or deletion of DNA) polymorphism in a region 
known as the 5-HTT gene-linked polymorphic region 
(5-HTTLPR). A polymorphism in this region can alter tran-
scriptional efficiency (production) of the transporter protein 
itself causing problems with the regulation of serotonin.38,39 
About 40 percent of the North American population, espe-
cially in populations of European ancestry, have a genetic 
variation in 5-HTTLPR which is associated with reduced effi-
cacy of SSRis, a slower overall onset of treatment, and often 
times an indication for a change in therapy.16 The short (S) 
Slow Enzymatic Activity *5,*6,*7,*14,*17,*22 
Rapid Enzymatic Activity *11, *12, *13, *18, *20, *21, *23, *24, *25, *27 
No Enzymatic Activity *15, *19A, *198 
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allele is associated with lower transcriptional efficiency of 
5-HTT (due to a deletion with an overall length of 44 base 
pairs), whereas the long (L) allele maintains normal tran-
scriptional efficiency of 5-HTT.3B-40 Patients will contain one 
of three possible allele pairs (genotypes) including homozy-
gous L/L, heterozygous S/L and homozygous S/s.1 De-
pressed patients containing the L/L or L/S variant genotypes 
have demonstrated a better response to SSR!s than those 
patients with the S/S (short) variant.1 Although the L allele is 
significantly associated with better treatment outcomes with 
SSRI therapy, it is unclear exactly why the L allele would con-
fer a favorable outcome. One proposed mechanism surmises 
that the L allele makes the HTTLPR region better able to 
regulate the transporter's response to dynamic changes in 
extracellular concentrations of 5-HT; such as those affected 
by environmental changes and/or administration of SSR!s 
(mainly due to the activation of a stronger feedback mecha-
nism).41 Some more recent studies now suggest that the 
presence of promoter binding elements may increase with 
antidepressant treatment due to evidence from a differential 
effect (the effect of applying one treatment instead of the 
other) with the promoter region insertion.41 Other studies 
have proposed possible mechanisms explaining the associa-
tion between the L allele and better treatment outcomes, 
however, future research should evaluate these mechanisms 
to define a more distinct answer. Furthermore, studies have 
not researched the possible genotype effect on a dose re-
sponse curve which would indicate whether dosing could 
optimize antidepressant treatment based on the patient's 
genotype.41 Clinically, there are no clear recommendations 
for dosing medications based on individual genotypes, how-
ever, educating patients about their individual genotypes can 
be beneficial in optimizing treatment. Patients carrying a 
genotype that is associated with a less beneficial treatment 
outcome compared to others should be made aware of possi-
ble alternative approaches if SSRI treatment fails. In addition, 
patients could also be encouraged to try alternative therapies 
due to the different mechanisms that other treatments tar-
get. 
Clinical Relevance 
Jn addition to genetic differences related to PK, drug-drug 
interactions also have their place regarding antidepressant 
dosing and medication choice. Citalopram primarily under-
goes its metabolism by the enzymes CYP3A4 and CYP2C19 
while sertraline is subject to CYP206 metabolism.42.43 These 
SSR!s, both of which are in the top 20 most prescribed drugs 
of 2012, demonstrate a high potential for interaction with 
medications sharing the same enzyme.44 The easy-to-acquire, 
over-the-counter proton pump inhibitors, omeprazole and 
lansoprazole, also require metabolism by CYP2Cl 9 and can 
decrease the metabolism of other 2Cl 9-dependent medica-
tions.43 These enzymes are also known metabolizers of many 
of the top 100 prescribed drugs, and substrates of these en-
zymes may compete for the enzyme's activity, resulting in a 
drug-drug-gene interaction known as a phenotype conver-
sion or phenoconversion. These interactions can either be 
synergistic or antagonistic and can enhance or decrease a 
drug's effect, respectively, possibly rendering a previous EM 
toa UM or PM. 
With knowledge of patients' genotypes, both pharmacists 
and prescribers are able to personalize therapy and provide 
the optimal drug and/or dose for better patient outcomes. 
Depression and mental disorders can now be managed accu-
rately and aggressively, and traditional guess-and-check 
methods will no longer need to be employed for starting anti-
depressant treatment. In a recent study by Ferreri and asso-
ciates, community pharmacists performed PGt testing for the 
CYP2Cl 9 genotype in patients currently taking clopidogrel.45 
The CYP2Cl 9 enzyme is responsible for converting the 
prodrug, clopidogrel, to its active metabolite, and its gene is 
found to have at least one loss-of-function allele in 30 per-
cent of the population.46,47 It was found that half of the pa-
tients in the study had at least one variant allele (*2 or *17). 
Recommendations of therapy were made by the pharmacist 
based on the genotype outcome, and were approved by the 
prescriber 89 percent of the time.45The remaining 11 per-
cent consisted of therapy changes, including the prescriber 
knowing the patient's intolerability (via prior experience) to 
the suggested treatment, and a discontinuation of clopidogrel 
for a patient not supposed to be receiving it. The knowledge 
of a patient's genotype allowed the pharmacists to make rec-
ommendations to change therapy and perhaps improve out-
comes in 50 percent of those who participated. 
This study demonstrates the potential for pharmacists' ge-
netic testing in a community setting and direct involvement 
with improving patients' health and well-being. Initiation of a 
collaborative agreement between providers (prescriber and 
pharmacist) will help to streamline therapy regimens and 
decrease any risk of drug-drug or drug-gene interactions. A 
comprehensive medication review will most likely become 
required with PGx testing as to eliminate any potential for 
adverse events. The possibility to improve outcomes exists 
prior to initiating treatment by ordering testing upon diagno-
sis, whether by a primary care physician, specialist or a 
clinical pharmacist. For antidepressants, preemptive genetic 
testing before prescribing can provide the greatest immedi-
ate benefit by determining an effective medication with 
which to begin treatment. 
Significant barriers exist for implementing PGx testing, espe-
cially in a community pharmacy setting. The average time 
spent by a pharmacist from initially performing the testing 
and communicating with prescribers to counseling the pa-
tient totals over one hour, with lab results averaging over 
five days, and almost two weeks to receive approval from the 
prescriber.45 At first glance, this laborious process can be 
seen as a suboptimal business model in the world of fast 
paced retail chains, but as health care information technol-
ogy catches up with this blueprint of highly integrated transi-
tion of care, we can expect this timeline to dramatically de-
crease. Billing and reimbursement also remain a factor as all 
claims sent to medical insurance companies, including Medi-
care Part D plans, were initially rejected for having the phar-
macist listed as the provider, and not the prescriber. Also 
related to cost are the implications of PGx testing and its 
overall cost/benefit profile for antidepressant drugs. Addi-
tional research is necessary to provide solid evidence dis-
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playing increased patient remission rates for depression di-
rectly related to genetic testing. 
Fortunately, all of these barriers can be overcome with cor-
rect implementation of health care information technology 
and laws. As more and more clinically relevant outcomes are 
proven relating an individual's genotype to his or her drug 
response, we can expect to see a paradigm shift in the pre-
scribing and treatment regimen for antidepressant medica-
tions as well as other CYP dependent medications. Over 130 
FDA-approved drugs currently include PGx information in 
the package labeling, with 30 of them being classified for psy-
chiatry and/or neurology.29 The increase in evidence will 
help validate the need for genetic testing and, combined with 
the decreasing cost of DNA sequencing, will accelerate the 
acceptance of reimbursement by insurance companies. 
Conclusion 
Pharmacists maintain a major role in applying and utilizing 
personalized medicine and are beginning to base many 
clinical decisions on PGt in both the community and health-
systems setting. Personalized medicine is reaching antide-
pressant therapy due to the increased research in PGt and 
the reduction of cost in genetic testing.17 Pharmacists can 
utilize genetic information to help primary care physicians 
choose drug regimens that are more likely to be beneficial to 
their patients. Pharmacists can also make recommendations 
to patients' diet and lifestyle choices (e.g., smoking) that 
might cause an increase or decrease in drug efficacy. It is also 
important for pharmacists to be aware of medications that 
may induce or inhibit the normal enzymatic activity and to 
understand what enzymes are major metabolic pathways of 
each drug which ultimately affects what treatment regimens 
are chosen. 
The future of personalized medicine, including PGt testing 
related to PK and PD, could ultimately lead to better clinical 
outcomes. Studies show that patients utilizing individualized 
therapy based on genotypes have better outcomes and 
achieve efficacious therapeutic regimens quicker. Although 
most antidepressant treatment does not have distinct 
pharmacotherapy guidelines based on polymorphisms, the 
expectation is that more extensive research will result in the 
development of guidelines for dosing and drug selection 
based on patient genotypes. Nevertheless, pharmacotherapy 
adjustment guidelines are currently seen for drugs in dis-
eases that present less complex heritability models such as 
warfarin and clopidogrel.39 Recently, many discoveries have 
been made toward the pathophysiology of mood disorders 
and their treatment mechanisms, however a major target for 
research should be to evaluate the efficacy of therapies and 
dosing based on patient genotypes. Another major target for 
future research is the development of genotyping kits at 
lower costs in order to individualize patient treatments more 
effectively.39 Genotyping, especially for patients on antide-
pressants, will prevent the primary care physician from hav-
ing to use trial and error prescribing to find an effective drug 
and dose for their patients. Furthermore, screening a pa-
tient's genotype eliminates therapeutic options that would 
have been deemed effective in most other patients. 
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